ClinicalTrials.gg
CompletedNCT02105129Updated Apr 28, 2016

A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523

A Phase 1 interventional study of HMPL-523 and Placebo in Rheumatoid Arthritis (RA), sponsored by Hutchison Medipharma Limited. Completed at 1 site in Australia. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-28.

Sponsored by Hutchison Medipharma Limited (part of HUTCHMED) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 154 studies in Arthritis, Rheumatoid with a site in Australia — 16 open to participants now, 21 under way, 3 of them phase 3. Arthritis, Rheumatoid · Australia.

Enrollment
113th of 140
118 · median 469
Started
2014
with 4 others
Phase 1
21 of 154
12 open now
Registered
94th of 154
by date

Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, this one is the 113th largest by enrollment of the 140 interventional ones that give a count, is one of 5 that started in 2014, is one of 21 in phase 1, and was the 94th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

16 of the 154 studies in Arthritis, Rheumatoid with a site in Australia are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Arthritis, Rheumatoid with a site in Australia, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the safety and tolerability of a single dose of up to 800 mg in Part A (evaluated in planned steps of 5, 20, 50, 100, 200, 300 mg under fasted conditions, followed by 300, 400, 600 and 800 mg HMPL-523 under fed conditions of a standard meal, followed by multiple doses of 200, 300, 400 and 500 mg of HMPL-523 in Part B, in healthy male volunteers.

The secondary objective is to determine the pharmacokinetic profile of single (Part A) and multiple (Part B) oral doses of HMPL-523 in healthy male volunteers and to determine the preliminary effect of food (Part C)

Read the detailed description

This is a Phase I study with 3 parts:

Part A: Double blind, randomized, placebo-controlled, dose-escalating, single dose study in healthy volunteers.

Part B: Double blind, randomized, placebo-controlled, dose-escalating, multiple dose study in healthy volunteers.

Part C: Open labeled, single dose, cross-over, preliminary food effect study in healthy volunteers.

Number of subjects:

Part A: 80 healthy volunteers (10 cohorts of 8 subjects) Part B: About 40 healthy volunteers (5 cohorts of 8 subjects) In Part B, the multiple doses are 200(Cohort B1), 300(Cohort B2), 400(Cohort B3), and 500 mg(Cohort B4) and 8 subjects will be enrolled in each cohort. At dose 200mg, additional cohort (Cohort B1a) with 8 subjects needs to be enrolled based on the clinical data (safety, tolerability, available PK data and clinical laboratory values). The decision is made jointly by the Principal Investigator and the sponsor. Within each cohort, 6 subjects will receive HMPL-523 and 2 subjects will receive placebo Part C: 6 healthy volunteers (1 cohort; all will receive HMPL-523 100 mg).

Treatments:

-Part A: Single Ascending Dose.Subjects will receive a single dose of up to 800 mg HMPL-523 or matching placebo during Day 1. The planned dose levels are: 5, 20, 50,100, 200, 300 mg under fasted conditions, followed by 300, 400, 600, 800 mg under fed conditions with a standard meal, according to the randomization schedule. Dose levels may be repeated, reduced or administered as a split dose if deemed appropriate by the Principal Investigator and Sponsor's medical Expert.

For Cohort 1 a sentinel group (1 HMPL-523 and 1 placebo) will be dosed at 5 mg HMPL-523, 24 hours prior to the planned dosing of the remaining six subjects. Dosing of the remaining six will be based on investigator judgment. The decision to dose escalate will be made jointly by the Principal Investigator and the sponsor based on the clinical data (safety, tolerability, available PK data and clinical laboratory values).

-Part B: Multiple Ascending Dose (MAD). Part B of the study has been designed to assess the effects of multiple ascending doses of HMPL-523 in healthy volunteers. The total daily doses and dosing regimen for Part B have been determined as 200, 300,400 and 500 mg based on the review of safety and PK data from Part A, made jointly by the Principal Investigator and the sponsor. The dose will be the same or less than one already administered to participants in Part A. Because dog has similar protein binding to humans, we will closely monitor the clinical safety and laboratory result when the AUC is getting to 2085 h*ng/mL, which is the NOAEL AUC in dogs. Further dose escalation will be based on clinical safety and discussion between the sponsor and the investigators.

Part C: Preliminary Food Effect Study. Part C of the study has been designed to preliminarily assess the effect of food on the pharmacokinetics of HMPL-523 in healthy volunteers. Subjects will first receive a single dose of HMPL-523 100mg under fasted conditions (Period 1) and then following a washout period of 7 days, will receive a single dose of HMPL-523 100mg after consuming a standard high fat breakfast (fed conditions) (Period 2). Part C may be conducted at any time, provided 100 mg has been deemed safe in Part A.

Safety data:

The following safety evaluations will be performed during the study: Adverse events, physical examination, clinical safety laboratory (hematology, clinical chemistry, urinalysis), body weight, oral temperature, triplicate blood pressure and heart rate , and ECG .

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • must be obtained in writing for all subjects before enrollment into the study
  • Healthy male subjects aged 18 to 45years inclusive at the time of screening
  • ≥19.0 and ≤ 30.0 kg/m2
  • No abnormalities as determined by medical history and physical examination, especially with regard to the liver, bile and gastrointestinal systems
  • No clinically significant laboratory values and urinalysis, as determined by the clinical Investigator.
  • No clinically significant findings in , blood pressure and heart rate, as determined by the clinical Investigator.
  • Willing to comply with the requirements of the study and must not donate sperm during the study or for 3 months afterwards. Subjects must agree to use a condom or to abstain from sexual intercourse throughout the trial and for 30 days afterwards.

Exclusion criteria

Exclusion Criteria:

  • Family history of premature Coronary Heart Disease
  • Any condition requiring the regular use of any medication
  • Exposure to prescription medications or to drugs known to interfere with metabolism of drugs within 30 days prior to Day 1
  • Exposure to any other medication, including over-the counter medications, herbal remedies and vitamins 14 days prior to first dose
  • Participation in another study with any drug in the 30 days preceding Day 1 of the study
  • Treatment in the previous 3 months with any drug known to have a well defined potential for toxicity to a major organ
  • Current smoker of more than 10 cigarettes or equivalent / day prior to commencing the study and unable to completely stop smoking during the study
  • Be in the exclusion period of any previous study with investigational drugs
  • Symptoms of a illness in the 3 months before the study
  • Presence or sequelae of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
  • Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease, Hemorrhoids or anal diseases with regular or recent presence of blood in feces
  • History of significant allergic disease (e.g. Allergic to medications) and acute phase of allergic rhinitis in the previous 2 weeks before randomization or any food allergy
  • Blood or plasma donation of more than 500 ml during the previous 30 Days before randomization and/or more than 50 ml in the 2 weeks prior to screening
  • Known positive test for
  • Known positive test for or C, unless caused by immunization
  • Current evidence of drug abuse or history of drug abuse within one year before randomization
  • History of alcohol abuse or active alcoholism as defined in Appendix A Definition of alcohol abuse
  • Mental condition rendering the subject incapable to understand the nature, scope, and possible consequences of the study
  • Adults under guardianship and people with restriction of freedom by administrative or legal decisions
  • Unlikely to comply with the clinical study protocol; e.g. uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study
  • Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    HMPL-523

    Single/Multiple Ascending Dose. oral administration, a single dose of 5, 20, 50, 100, 200 and 300 mg (Part A) and multiple dose of HMPL-523 at dose level based on result of Part A

    Drug: HMPL-523

  • Placebo comparator
    Placebo

    Placebo: oral administration

    Drug: Placebo

Interventions

  • HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA

    Also known as: HMPL-523 acetate

  • DrugPlacebo

    Oral administration

    Also known as: HMPL-523 Placebo

06

What researchers measure

Primary outcomes

  1. To assess number of participants with adverse events as a measure of safety and tolerability during dose escalating

    Time frame: 6 months

Secondary outcomes

  1. To measure the plasma concentration of HMPL-523 in single and repeated doses

    Time frame: 6 months

07

Study locations

1 site
  • Nucleus Network Limited
    Melbourne, Victoria 3004, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2014
First posted
Apr 7, 2014
Start
May 2014
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Last update
Apr 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02105129
Responsible party
Sponsor
First posted
Apr 7, 2014
Start date
May 2014
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Apr 28, 2016

Study contacts

Jason Lickliter, MD
principal investigator · Nucleus Network Ltd
Yan Wu, MD
study director · Hutchison Medipharma Limited

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovleplenib

Start the discussion